동물용 혈장 제품 및 유도체 시장 : 동물 유형, 유도체 유형, 최종사용자, 용도별 - 세계 예측(2025-2030년)

The Animal Blood Plasma Products & Derivatives Market was valued at USD 1.52 billion in 2024 and is projected to grow to USD 1.63 billion in 2025, with a CAGR of 7.71%, reaching USD 2.37 billion by 2030.

Animal blood plasma products and derivatives have steadily emerged as a critical focus in both research and industrial applications. Over the years, the market has experienced significant growth driven by the expanding need for high-quality biological materials in various sectors. This in-depth report provides an expansive view of the industry, elucidating the evolution from traditional methodologies to innovative, science-driven solutions that meet modern-day challenges.

The industry now stands at the crossroads of scientific advancement and market demand. Fueled by increased investment in biotechnology and progressive research efforts, significant breakthroughs in extraction and purification processes have optimized the efficacy of animal plasma derivatives. These improvements have also translated into enhanced quality and reliability, making the products indispensable across multiple applications. As the demand grows, new safety, regulatory, and technological benchmarks continue to evolve.

This comprehensive analysis delves into key market drivers, laying the groundwork for a discussion on transformative shifts and segmented insights. The report also examines the nuances of regional growth, the strategies of industry-leading companies, and actionable insights for decision-makers. The role of research in refining existing products while also exploring novel derivatives is underscored, highlighting a market that is both dynamic and forward-thinking. With an ever-increasing need to balance quality, cost, and regulatory requirements, the overview sets the stage for a detailed exploration of the market's promising future.

Transformative Shifts Impacting the Industry Landscape

Recent years have witnessed several transformative shifts in the animal blood plasma products and derivatives market. Innovations in processing techniques combined with advanced analytical tools have reshaped production efficiency and product quality. Enhanced purification methods now allow for greater consistency in derived products, meeting both stringent regulatory criteria and evolving consumer expectations.

The market has also been influenced by notable technological advances, including automation in production lines, integration of artificial intelligence for quality control, and data-driven approaches to process optimization. These changes have not only reduced manufacturing costs but have also improved the scalability of production, enabling manufacturers to meet surging global demand. Simultaneously, evolving regulatory landscapes have compelled companies to enhance transparency and compliance, directly impacting market operations and long-term strategies.

Simultaneously, industry players are increasingly investing in R&D to explore new applications that extend the traditional boundaries of animal plasma derivatives. There is a clear trend toward interdisciplinary collaborations and partnerships which further accelerate product innovation. With increasing demand in both emerging and established markets, manufacturers are redefining product portfolios to address a broader array of applications ranging from biomedical research to consumer products. These strategic shifts underscore a market in flux, where technological innovation and regulatory evolution are paving the way for sustained industry growth.

Key Segmentation Insights in the Evolving Market

A detailed segmentation analysis provides a clear window into the market dynamics of animal blood plasma products and derivatives. The industry is segmented based on animal type, derivative type, end-user, and application. In terms of animal type, significant emphasis is placed on products derived from avian, bovine, ovine, and porcine sources. Each of these categories brings distinct characteristics that cater to specific product needs in various applications.

Furthermore, the derivative type segmentation encompasses essential products such as fetal bovine serum, fibrinogen, immunoglobulin, serum albumin, and thrombin. These components are fundamental in a wide range of biomedical applications, contributing to both research and therapeutic practices. The end-user segmentation spans food manufacturers, pharmaceutical companies, and veterinary services. This diversity demonstrates the versatility and broad applicability of plasma products in addressing industry-specific challenges.

Application-based segmentation further underscores the market's evolving nature, with products making their mark in areas like animal feed, biomedical research, cell culture media, and food processing. Additional applications include nutrition supplements, pet food industry formulations, pharmaceuticals and cosmetics, as well as tissue engineering. This segmentation insight suggests that the market is highly specialized, with each segment reflecting distinct consumer requirements and technological innovations which drive both product development and strategic market positioning.

Based on Animal Type, market is studied across Avian, Bovine, Ovine, and Porcine.

Based on Derivative Type, market is studied across Fetal Bovine Serum, Fibrinogen, Immunoglobulin, Serum Albumin, and Thrombin.

Based on End-User, market is studied across Food Manufacturers, Pharmaceutical Companies, and Veterinary.

Based on Application, market is studied across Animal Feed, Biomedical Research, Cell Culture Media, Food Processing, Nutrition Supplements, Pet Food Industry, Pharmaceuticals & Cosmetics, and Tissue Engineering.

Essential Regional Insights Shaping Market Trends

The animal blood plasma products and derivatives market exhibits noteworthy regional variations that reflect broader economic, regulatory, and technological influences. In the Americas, robust growth is underpinned by advanced research facilities, a strong biotechnology sector, and an aggressive approach to regulatory compliance. These factors ensure sustained demand among established industry players as well as emerging enterprises. Meanwhile, this region benefits from extensive partnerships that drive innovation and set the pace for quality enhancements in product formulations.

Across the region encompassing Europe, the Middle East, and Africa, the market is evolving at a measured pace. Technological advancements and rigorous quality standards have positioned these areas as key contributors to in-depth scientific research and product development. Companies in this region are strategically investing in state-of-the-art infrastructure and R&D, which has resulted in notable improvements in process efficiency and product consistency. The emphasis on research collaboration and regional regulatory alignment has further facilitated market penetration and international trade.

In the Asia-Pacific region, rapid industrialization coupled with a growing demand for high-quality biologics has established an impressive growth trajectory. Technological integration and increasing investment in biotechnology have catalyzed local market innovation, positioning the region as a critical hub for both production and research. The interplay of these regional insights demonstrates that while each geographic area presents unique challenges, collectively they contribute to a resilient and forward-moving market landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Market Growth

The landscape of animal blood plasma products and derivatives is bolstered by the significant contributions of several key market players who not only drive innovation but also contribute to market stability and growth. Leading companies such as ACROBiosystems Inc. and Alfa Laval Corporate AB contribute through cutting-edge research and by setting high production standards in the field. Organizations including ANZCO Foods Limited and Auckland BioSciences Ltd. have expanded the market reach by integrating advanced production facilities with global distribution channels.

Other prominent players, including BioChemed Services, Biowest Company, and Bovogen Biologicals Pty Ltd., further enhance the product quality spectrum by focusing on state-of-the-art derivatization practices. Companies like Canvax Reagents S.L. and Ebrator Biochemicals Inc. emphasize innovation and technological frontiers to ensure that products not only meet but exceed industry standards. Moreover, the contributions of Kraeber & Co. GmbH, Lake Immunogenics, Inc., and LAMPIRE Biological Laboratories, Inc. span global markets by combining research excellence with operational efficiency.

In addition, industry leaders such as Meiji Holdings Co., Ltd., Merck KGaA, and Pel-Freez, LLC have cemented their positions through significant R&D investments that drive competitive advantages. The market also benefits from the strategic insights provided by organizations like Rockland Immunochemicals, Inc., Rocky Mountain Biologicals, Scripps Laboratories, Inc., and Sigma-Aldrich. Collaborations and technological synergies with TCS Biosciences Ltd. and Thermo Fisher Scientific Inc. have led to innovative product lines and enhanced service offerings, thereby reinforcing the market's future prospects.

The report delves into recent significant developments in the Animal Blood Plasma Products & Derivatives Market, highlighting leading vendors and their innovative profiles. These include ACROBiosystems Inc., Alfa Laval Corporate AB, ANZCO Foods Limited, Auckland BioSciences Ltd., BioChemed Services, Biowest Company, Bovogen Biologicals Pty Ltd., Canvax Reagents S.L., Ebrator Biochemicals Inc., Kraeber & Co. GmbH, Lake Immunogenics, Inc., LAMPIRE Biological Laboratories, Inc., Meiji Holdings Co., Ltd., Merck KGaA, Pel-Freez, LLC, Rockland Immunochemicals, Inc., Rocky Mountain Biologicals, Scripps Laboratories, Inc., Sigma-Aldrich, TCS Biosciences Ltd., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry decision-makers are positioned to accelerate growth by focusing on advancements in R&D and by streamlining operational efficiencies. Leaders should prioritize investment in next-generation processing technologies that elevate product purity and yield. It is essential to foster strategic partnerships that bridge research institutions with production facilities to harness cutting-edge developments and meet the changing market demands. By actively monitoring regulatory updates and aligning with global standards, companies can mitigate compliance risks while maintaining a competitive edge.

Furthermore, optimizing the supply chain and enhancing quality control measures will support timely market entry and reduce production bottlenecks. Establishing robust data analytics frameworks provides actionable intelligence that informs decision-making processes and tailors product development to the precise needs of diverse market segments. Ultimately, a focused approach that couples technological innovation with operational excellence will enable industry leaders to sustain growth and capitalize on emerging opportunities.

Conclusion and Future Market Prospects

The analysis of animal blood plasma products and derivatives reveals an industry rich in opportunity and resilient against market fluctuations. Driven by technological advancements, insightful segmentation, and an evolving regulatory environment, the market continues to demonstrate robust growth. The integration of innovative production techniques and diversification across various applications has created an ecosystem where research and development lead to tangible, market-ready outcomes.

As the industry moves forward, it is clear that embracing both regional nuances and the strategic insights of key companies will be instrumental in shaping future directions. The balance between quality enhancements and regulatory compliance continues to be a defining factor in enabling market leaders to achieve sustained success. With continued innovation and strategic collaborations, the prospects for the market remain highly promising, offering growth potential that is both extensive and diverse.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for animal meat and protein among human population
    • 5.1.1.2. Rising consumer awareness concerning sustainable and humane animal farming practices globally
    • 5.1.1.3. Expanding utilization of animal blood plasma in veterinary care applications
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations for safety and quality standards for animal blood plasma products
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging use of blood plasma derivatives in cosmetics and skincare for innovative product development
    • 5.1.3.2. Ongoing innovations in biotechnology and processing techniques to improve the quality of animal blood plasma products
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of synthetic alternatives to animal blood plasma products
• 5.2. Market Segmentation Analysis
  • 5.2.1. Animal Type: Rising preference for porcine plasma products owing to high efficiency and amino acid
  • 5.2.2. Application: Increasing significance of animal blood plasma products in pet food industry
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Animal Blood Plasma Products & Derivatives Market, by Animal Type

• 6.1. Introduction
• 6.2. Avian
• 6.3. Bovine
• 6.4. Ovine
• 6.5. Porcine

7. Animal Blood Plasma Products & Derivatives Market, by Derivative Type

• 7.1. Introduction
• 7.2. Fetal Bovine Serum
• 7.3. Fibrinogen
• 7.4. Immunoglobulin
• 7.5. Serum Albumin
• 7.6. Thrombin

8. Animal Blood Plasma Products & Derivatives Market, by End-User

• 8.1. Introduction
• 8.2. Food Manufacturers
• 8.3. Pharmaceutical Companies
• 8.4. Veterinary

9. Animal Blood Plasma Products & Derivatives Market, by Application

• 9.1. Introduction
• 9.2. Animal Feed
• 9.3. Biomedical Research
• 9.4. Cell Culture Media
• 9.5. Food Processing
• 9.6. Nutrition Supplements
• 9.7. Pet Food Industry
• 9.8. Pharmaceuticals & Cosmetics
• 9.9. Tissue Engineering

10. Americas Animal Blood Plasma Products & Derivatives Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Animal Blood Plasma Products & Derivatives Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Animal Blood Plasma Products & Derivatives Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Gemini Bioproducts expands its portfolio by acquiring Bio-Techne's key fetal bovine serum brands
  • 13.3.2. FDA clearance of PrecisePRP Canine transform veterinary care with innovative platelet-rich plasma solution
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ACROBiosystems Inc.
• 2. Alfa Laval Corporate AB
• 3. ANZCO Foods Limited
• 4. Auckland BioSciences Ltd.
• 5. BioChemed Services
• 6. Biowest Company
• 7. Bovogen Biologicals Pty Ltd.
• 8. Canvax Reagents S.L.
• 9. Ebrator Biochemicals Inc.
• 10. Kraeber & Co. GmbH
• 11. Lake Immunogenics, Inc.
• 12. LAMPIRE Biological Laboratories, Inc.
• 13. Meiji Holdings Co., Ltd.
• 14. Merck KGaA
• 15. Pel-Freez, LLC
• 16. Rockland Immunochemicals, Inc.
• 17. Rocky Mountain Biologicals
• 18. Scripps Laboratories, Inc.
• 19. Sigma-Aldrich
• 20. TCS Biosciences Ltd.
• 21. Thermo Fisher Scientific Inc.